Research programme: angiogenesis inhibitors - Bayer Schering Pharma/Novartis

Drug Profile

Research programme: angiogenesis inhibitors - Bayer Schering Pharma/Novartis

Alternative Names: AAL-993; ABP 309; Angiogenesis inhibitors research programme - Bayer Schering Pharma/Novartis; ZK-260255

Latest Information Update: 23 Mar 2010

Price : $50

At a glance

  • Originator Bayer Schering Pharma; Novartis
  • Class Amides; Anthranilic acids
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 29 Dec 2006 Schering AG is now called Bayer Schering Pharma AG
  • 19 Oct 2004 Data presented at the 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2004) have been added to the pharmacokinetics and Cancer pharmacodynamics sections
  • 06 Sep 2004 Data presented at the XVIIIth International Symposium on Medicinal Chemistry (ISMC-2004) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top